Introduction

From the 1960's to late 1980's, intramuscular (IM) injection of vitamin K (VK)
prophylaxis to neonates was the route universally adopted in many industrialised countries to prevent VK deficiency bleeding (VKDB), a rare and potentially life-threatening bleeding disorder in early infancy. 1 In the 1990's, UK studies reported an association between IM but not oral VK administration and childhood cancer, particularly leukaemia. 2, 3 Countries responded in different ways; several European countries moved towards a uniform policy of oral prophylaxis. 1 In the UK, regimens became varied, with numerous permutations of preparation used, route of administration, dose, and number of doses. 1 In Australia and New Zealand, an initial change to universal oral prophylaxis was later reverted to IM injection prophylaxis after cases of late VKBD reappeared, attributed to poor efficacy and/or compliance of oral VK. 4, 5 Australia continues to exercise caution, recommending IM injection of VK as the preferred route and providing oral prophylaxis of three doses given at birth, at 3-5 days of age, and in the fourth week of life as an alternative option for parents. 4 There is little evidence on parental characteristics and choice of various modes of VK prophylaxis administration. Only one study examining health beliefs associated with low uptake of the measles, mumps and rubella (MMR) vaccine in the UK, also examined VK prophylaxis. 6 The investigators found that non-compliance with MMR vaccination was strongly associated with the use of complementary healthcare and rejection of VK prophylaxis. 6 Therefore, the purpose of this study is to compare maternal and infant characteristics by route of VK prophylaxis (IM injection compared to oral or none).
Methods
The New South Wales (NSW) Midwives Data Collection (MDC) is a legislated population-based surveillance system, which includes information on all babies born at ≥20
weeks' gestation or weighing at least 400 g. or from a combination of antenatal care models, had spontaneous labour, an analgesia-free delivery, a normal vaginal delivery in a birth center or a planned homebirth, and less likely to have neonatal hepatitis B vaccine ( Table 1) . Neonates who were preterm births and breastfeeding at discharge were significantly more likely to have received oral rather than IM VK.
Compared to neonates who received IM injection, neonates who had 'none' recorded on the form for VK were more likely to be planned deliveries at a birth center or planned homebirth that resulted in a hospital admission and to be admitted to a neonatal or special care unit during their birth admission; however, there was no significant difference between term and preterm births.
Discussion
To our knowledge, this is the first study to examine maternal and infant characteristics by mode of VK prophylaxis. Findings reveal that in Australia, parental decision to use oral or no VK prophlaxis is aligned with attitudes and preferences for a natural birth without medical interventions. This finding supports previous research on the health beliefs of parents with low uptake of other vaccines and suggests that IM prophylaxis of VK is unattractive to parents with concerns about the "medicalisation" of birth and the risks of the injection itself. 6 The generation of public debate and anxiety around IM prophylaxis of VK from scientific evidence is illustrated in other examples of reported associations, such as pertussis immunisation and encephalopathy of infancy, or MMR immunisation and autism, both of which have since been dismissed.
1
Of concern, neonates who were preterm births and those who were breast-fed at discharge were significantly more likely to have been administered VK orally compared to IM injection. Limited fetal stores of VK at birth, especially in preterm infants, and the low VK content of human milk places these infants at increased risk for VKDB. 1 Multiple oral doses are prescribed because a single dose only offers protection for approximately 4 weeks and infants exclusively breast-fed receive inadequate VK from breast milk. 4 Neonates recorded as not receiving any VK represent a relatively small group (1%); however, the absolute number is not inconsequential (n=3,136). Neonates in this group over-represented extremely ill babies who were admitted to a neonatal or special care unit and may have been administered VK later in treatment during their birth admission after the midwife had already been completed the MDC form. These neonates were more likely to have natural births without medical interventions and less likely to receive a hepatitis B vaccine, thus, it is possible that some missed out on VK prophlaxis because of parental safety concerns. Of note, the hepatitis B immunisation of infants is offered universally in NSW.
7
While VKBD is a rare disease, the consequences are severe. 1, 8 The Australian Pediatric Surveillance Unit (APSU) reported 6 confirmed cases of VKBD from 2007-2008, the majority of which were late onset VKDB. 5 Of those with a late onset, more than half had liver disease. 5 Most children with VKDB were found to have received insufficient or no VK at birth 5 . Two of three infants who died from VKDB were without liver disease and did not receive VK at birth. 5 Implications of a change in the mode of VK administration in newborns (introduction of oral preparations) is currently being examined in Australia. 4 Our study does not have details on infants where the VK record was missing data.
Subjects with blank entries represented a small percentage of cases (0.08%) and were excluded from analyses to avoid biasing results; however it would have been interesting to know whether missing cases related to parental choices, caregiver recommendations, or recording errors. The study also has limited generalizability. VK prophylaxis practices vary by country and results from this study may not pertain to other populations with different neonatal immunisation guidelines or parental preferences and knowledge of preventative practices. Study strengths include the size and validity of the population database used. 9 A small proportion of the Australian public remains concerned about the safety of IM injection of VK to neonates. It is impossible to give unequivocal reassurance on this point; current scientific evidence does not support an association between IM injection of VK and increased risk of cancer; however, it is not possible to exclude a small increased risk in leukaemia due to limitations of the data. 4, 8 Oral prophylaxis is easy and non-invasive; however, parents need to be informed of the disadvantages of uncertain absorption which can be adversely affected by vomiting or regurgitation and the reliance on parental compliance to administer multiple doses in early infancy to ensure neonates have full protection from developing VKDB.
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